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AbstrACt
Introduction The diagnosis of mild traumatic brain injury 
or sports-related concussion is a challenge for all clinicians, 
players, coaches and parents involved in contact sports. 
Currently, there is no validated objective biomarker available 
to assess the presence or severity of concussion in sport, and 
so it is necessary to rely on subjective measures like self-
reporting of symptoms which depend on the cooperation of 
the athlete. There is a significant health risk associated with 
repetitive injury if the diagnosis is missed, and so there is 
great value in an objective biomarker to assist diagnostic and 
prognostic decisions.
Objective To establish a panel of non-invasive MicroRNA 
biomarkers in urine and saliva for the rapid diagnosis of 
sports-related concussion and investigate the kinetics and 
clinical utility of these biomarkers in assisting diagnostic, 
prognostic and return-to-play decisions.
Methods and analysis Observational, prospective, 
multicentre cohort study recruiting between the 2017–2018 
and 2018–2019 Rugby Union seasons. Professional rugby 
players in the two highest tiers of senior professional domestic 
rugby competition in England will be recruited prospectively to 
the study. During the season, three groups will be identified: 
athletes entering the World Rugby Head Injury Assessment 
(HIA) protocol, uninjured control athletes and control athletes 
with musculoskeletal injuries. Saliva and urine will be 
collected from these athletes at multiple timepoints, coinciding 
with key times in the HIA protocol and return-to-play process.
Ethics and dissemination Ethics approval has been 
obtained. The compiled and analysed results will be 
presented at national and international conferences 
concerning the care of patients with traumatic brain 
injury. Results will also be submitted for peer review and 
publication in the subject journals/literature.
IntrOduCtIOn 
Sports-related concussion is a form of mild 
traumatic brain injury caused by biomechan-
ical forces transmitted directly or indirectly to 
the head and neck. Data from the Rugby Foot-
ball Union (RFU) indicate that concussion 
occurs at an incidence of 20.9/1000 player 
hours in elite-level Rugby Union in England.1 
In the majority of cases, concussion results in 
a rapid onset, but short-lived, impairment of 
neurological function that resolves sponta-
neously.2 It is accompanied by an absence of 
findings on conventional neuroimaging and, 
while 80%–90% of the sufferers are able to 
return to preinjury levels of neurocognitive 
and physical functions within 2 weeks, 2.5% 
go on to experience persistent postconcus-
sion symptoms (eg, headaches, dizziness, 
fatigue, memory problems).3 4 
Concussion incidence has increased in 
Rugby Union over recent years,1 however it is 
felt that this, at least in part, reflects a rising 
strengths and limitations of this study
 ► This study will contribute to a better understanding 
of the pathophysiology of sports-related concussion 
and the role of MicroRNAs within this.
 ► The study will prospectively recruit elite Rugby 
Union athletes entering the World Rugby Head Injury 
Assessment (HIA) protocol, before their diagnosis of 
sports-related concussion is confirmed, as well as 
elite athlete controls both with and without muscu-
loskeletal trauma injuries.
 ► This work will potentially provide a novel means of 
non-invasively and objectively diagnosing sports-re-
lated concussion and advising on decisions relating 
to symptomatic treatment and return-to-play.
 ► The study will allow for the modelling of this novel 
diagnostic tool in relation to an existing, robust and 
widely used multimodal concussion assessment 
process (the World Rugby HIA protocol) to under-
stand the value which might be added by salivary 
and urinary markers.
 ► This study will recruit from a population of elite male 
adult athletes and so applications to other popula-
tions, such as female and youth athletes, will require 
further study.
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awareness of the problem, rather than a true increase 
in rate. This mirrors a significant interest in this injury 
in the popular press generated in part by stories of cata-
strophic short-term consequences and persistent disability 
following concussions or repeated concussions along with 
extensive litigation in the USA.2 3 5
Despite the popular media attention surrounding concus-
sion, there remain a number of unanswered questions with 
regard to both the short-term and long-term consequences 
of this condition.6 The relationship between the cumulative 
burden of concussive and sub-concussive injuries and signif-
icant clinical outcomes remains uncertain. These outcomes 
include the later development of neurodegenerative disease 
such as chronic traumatic encephalopathy, the potential for 
catastrophic injury (second impact syndrome) following 
a premature return to head contact activities following 
concussion and the need for rehabilitation of patient 
suffering prolonged post concussive symptoms; all of which 
require further exploration. The issue of safe return to sport 
following concussion is of particular note here in light of 
evidence of a prolonged period of metabolic disturbance7 
and increased risk of subsequent injuries when returning to 
play,8 both of which outlast symptomatic recovery.
In part, the difficulty in answering these questions 
fully relates to the challenge of diagnosing concussion 
itself which continues to be an issue across all sports. It 
is recognised that the on-field assessment of players for 
signs and symptoms of concussion is challenging,9 10 and 
that there is at present no perfect test with which to diag-
nose concussion.
In order to combat current diagnostic uncertainty, 
expert consensus recommends the use of multimodal 
diagnostic tools, at multiple timepoints to allow for the 
varied and evolving presentations of concussion to be 
picked up by clinicians.9–13 However, the need for player 
engagement, the availability of clinicians, the need for 
baseline athlete information and the variation in diag-
nostic threshold between clinicians means that it is still 
challenging to establish a definitive diagnosis of sports-re-
lated concussion in athletes.
One example of sport attempting to facilitate diag-
nosis of concussion is the Head Injury Assessment (HIA) 
protocol in elite-level Rugby Union. This protocol has 
been described previously and has been evaluated and 
shown to reduce the proportion of players being allowed 
to continue playing after suffering a concussion.11 12
Briefly, players who demonstrate clear observable signs 
or symptoms of concussion (defined as conforming to 
any one of 11 ‘criteria 1’ signs or symptoms) following 
a head injury event either observed directly by medical 
staff or following video review or confirmed during an 
on pitch medical assessment (eg, loss of consciousness, 
tonic posturing, nystagmus) are permanently removed 
from the game without any further off-field concussion 
screening and, irrespective of further clinical evaluation, 
are considered to have sustained a concussion.
Where the outcome of a head impact event is not clear, 
for example if no criteria 1 signs or symptoms are identified 
but there is a suspicion that the injury mechanism may 
have resulted in a concussion (defined as conforming to a 
set of ‘criteria 2’ signs), the players undergo a standardised 
off-field assessment. This off-field screening assessment takes 
the form of the multimodal ‘HIA1’ assessment involving 
Maddock’s questions, symptom checklist, immediate and 
delayed recall, tandem gait test and assessment of clinical 
signs. A window of 10 min is permitted for this assessment 
to be conducted with the player being temporarily replaced 
in the game for that period. Any abnormality in the HIA1 
assessment and/or a clinical suspicion of concussion by the 
assessing practitioner mandates a permanent removal from 
play, but a diagnosis of concussion is not made or excluded 
at this time point. An electronic decision aid is used to assist 
this assessment with reference to baseline data collected in 
preseason for each player.
All players who undergo the HIA1 assessment, irre-
spective of outcome, have more detailed clinical assess-
ments postmatch (HIA2) and again after two nights 
rest (HIA3) to monitor their progress and confirm or 
exclude a diagnosis of concussion. The HIA2 assessment 
involves the use of the Sport Concussion Assessment 
Tool 5th edition,14 tandem gait test and clinical assess-
ment, while the HIA3 may also include the use of neuro-
cognitive testing (typically computerised tools such as 
Cogsport).
The diagnosis of concussion then is reached either 
during the game on the basis of the presence of stan-
dardised criteria 1 features, or in the 48 hours following 
the match on the basis of two subsequent clinical assess-
ments by the team physician at the HIA2 and HIA3 time-
points, supported by the standardised HIA2 or HIA3 
assessments conducted by the team physician.
Therefore this process divides players into three groups:
 ► Players who are immediately and permanently 
removed from the game on the basis of criteria 1 
features (immediate permanent removal) and diag-
nosed with concussion.
 ► Players who enter the HIA1 screening process and are 
not diagnosed with concussion following the comple-
tion of either of their HIA2 and HIA3 assessments.
 ► Players who enter the HIA1 screening process and 
are diagnosed with concussion at either their HIA2 or 
HIA3 assessments.
Away from elite sport, there is, if anything, more varia-
tion in the diagnostic thresholds and safe return-to-activity 
advice which is given to patients and military personnel. 
This is reflected in the most recent UK National Insti-
tute for Health and Care Excellence guidance which has 
highlighted the importance of traumatic brain injury 
biomarker research in head injury.15
MicroRNAs (miRNA) are a recently discovered class of 
non-coding RNAs that play key roles in the regulation of 
gene expression. They are attracting increasing interest 
in clinical research as potential biomarkers for the iden-
tification and classification of cancers as well as other 
disease states including neurodegenerative diseases and 
most recently, brain trauma.16–18 This is reflected in the 
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exponentially increasing number of publications on their 
use in a variety of medical applications.
Work by DiPietro and colleagues has demonstrated the 
value of serum miRNA in providing prognostic informa-
tion regarding the severity of traumatic brain injury in 
road traffic collision patients. Furthermore, this has been 
shown to be of value from very early timepoints, including 
at the roadside.16 In light of the potential challenges of 
using an invasive serum test in an athletic setting, follow-up 
work in the Birmingham Sport Concussion Clinic at the 
Queen Elizabeth Hospital Birmingham (QEHB) has 
looked at the presence of miRNA markers in the blood, 
saliva and urine of concussed athletic patients presenting 
to the clinic within 72 hours of injury and healthy controls. 
This has identified five miRNA markers which are upreg-
ulated in saliva following concussion, demonstrating the 
potential promise of this category of fluid biomarkers in 
assisting with this diagnostic challenge.19 Therefore, our 
objective is to establish a panel of non-invasive miRNA 
biomarkers in urine and saliva for the rapid diagnosis of 
sports-related concussion and investigate the kinetics and 
clinical utility of these biomarkers in assisting diagnostic, 
prognostic and return-to-play decisions.
MEthOds And AnAlysIs
study design
The Study of Concussion in Rugby Union through 
MicroRNAs (SCRUM) is a prospective observational 
cohort study of all male players (up to 1100) in the 
two highest tiers of senior professional domestic rugby 
competition in England, the Premiership and Champion-
ship. The study is embedded within the ongoing RFU’s 
Professional Rugby Injury Surveillance Programme for 
the 2017–2018 and 2018–2019 seasons.
All players will be visited at their club during the 
preseason period and provided with information about 
the study, including the processing and handling of their 
samples, the anonymisation of their data and their right 
to withdraw their voluntary consent at any time, before 
being asked to complete a consent form. They will then 
be asked to provide a single baseline sample of approxi-
mately 2 mL of saliva and about 5 mL of urine, if possible 
before their usual training session. These samples will 
provide the baseline miRNA values for a large popula-
tion of elite athletes and are taken alongside a baseline 
questionnaire which provides information on previous 
concussion history and symptoms.
In addition to this baseline collection from the players, 
the club medical teams will be visited and provided with 
an explanation of the study materials and sample-col-
lection procedures. This will be reinforced with regular 
email reminders during the season, the availability of the 
study team via telephone or email 24/7 to answer ques-
tions and an online video demonstrating the collection 
procedure (see online supplementary video).
During the season, each time a player enters the HIA 
process he will be asked for saliva sample at the HIA1 
timepoint and for saliva and urine samples at the HIA2 
and HIA3 timepoints. In this way, we will be able to inves-
tigate the presence of concussion diagnostic miRNAs 
non-invasively at multiple timepoints which are matched 
to a standardised clinical assessment and diagnostic 
threshold for concussion performed by a clinician with 
experience in rugby head injuries.12
Players diagnosed with concussion will be asked for 
a sample of saliva and urine at the point at which they 
are cleared by their team physician to return to rugby 
(stage V) as per the Berlin Consensus Graduated Return-
to-Play protocol.20 This will allow for the time course for 
recovery of the identified miRNA markers to be mapped. 
Data regarding the identification of players entering the 
HIA process and returning to play are collected weekly 
by the RFU and Premiership Rugby which will allow us to 
monitor compliance through the season and to analyse 
differences between incidents included and not included 
in our data collection.
Whenever a player enters the HIA process, club 
medical teams will also be asked to approach an ‘unin-
jured control’ player for saliva and urine samples at the 
HIA2 and HIA3 timepoints. An ‘uninjured control’ is a 
non-concussed player who has played approximately a 
matched number of minutes in the same game. This will 
allow for the description of miRNA profiles in response 
to the physical stress of athletic activity and exposure to 
the likely sub-concussive blows which come from partici-
pation in a collision sport.
To rule out contamination from non-neurological inju-
ries and musculoskeletal trauma, club medics will also be 
asked to collect samples from players removed from the 
field of play due to musculoskeletal injuries (orthopaedic 
controls) at the same timepoints as the ‘uninjured control’ 
group. The matching ratio for these groups (concussion, 
uninjured controls and orthopaedic controls) will be 
1:1:1 (see table 1).
The samples will be collected in Oragene-RNA saliva 
collection pots and Norgen Biotech urine sample pots, 
both of which contain a proprietary miRNA stabilising 
solution. The samples will be transported to the Univer-
sity of Birmingham (UoB) where they will be processed 
in line with the sample manufacturer’s guidance to allow 
freezing and storage.
A next-generation sequencing (NGS) procedure will be 
carried out by the RNA sequencing services of Exiqon on an 
unbiased preliminary selection of an estimated 20 samples 
in each of the different players groups. NGS allows the iden-
tification of all potential non-coding RNAs that are differ-
entially expressed between study groups. The NGS analysis 
will potentially identify a number of suitable candidate 
biomarkers. To correct for the effect of multiple compari-
sons, we will apply the Benjamini-Hochberg procedure to 
select biomarkers with a false discovery rate <0.05 for further 
analysis by quantitative PCR in the whole population of 
study samples. From the surviving panel, we will exclude 
biomarkers whose concentrations are not significantly 
different from matched baseline values (p>0.05).
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sample size
The RFU estimates that out of the 1100 players partic-
ipating in the top two tiers of English rugby (The 
Premiership and Championship) each season, 350–400 
players enter the HIA process, of whom approximately 
200 will be diagnosed as concussed. If participation was 
universal, the study would generate approximately 3500 
saliva samples and 2900 urine samples from the following 
cohorts during the course of a season:
 ► 1100 players tested preseason.
 ► Approximately 200 players will provide repeat base-
line samples in the postseason. This will allow for 
quality control for intraindividual variation from 
season to season.
 ► 200 players with a definitive diagnosis of concus-
sion following either identification of criteria 1 signs 
in-game or following the HIA2 and HIA3 assessments 
in the 48 hours postgame.
 ► 150–200 players temporarily removed from play for 
an off-field assessment following a head injury event 
(possible concussion) but for whom concussion is 
not subsequently confirmed following the HIA2 and 
HIA3 assessments in the 48 hours postgame.
 ► 200 matched controls with musculoskeletal injuries 
tested twice.
 ► 200 matched uninjured controls tested twice.
Outcome measures and statistical analysis
Biomarker data will be analysed with standard group 
comparison statistics (eg, t-test on normalised data or 
Mann-Whitney on non-normalisable data).
Primary outcome(s)
The primary outcome measure will be the postmatch 
(HIA2) comparison of levels of a panel of miRNAs in 
saliva and urine samples from players who have been 
definitively diagnosed with concussion through the HIA 
process described above versus players in the uninjured 
and musculoskeletal injury control groups described 
above.
Secondary outcomes
Secondary outcomes are:
 ► Kinetics of the sample biomarkers at the different 
timepoints outlined in the protocol above in table 1.
 ► We will also report HIA1, 2 and 3 levels of the same 
miRNA panel for players entering the HIA process 
who were not eventually diagnosed with concussion.
 ► Correlation between levels of specific biomarkers and 
severity, type and duration of symptoms as well as time 
to return to full participation.
Patient and public involvement
The Rugby Players’ Association is the representative body 
for professional players in England and has been involved 
from the outset, with members asked to share their views 
on the design and setting up of this study. They are also 
part of the steering and oversight group. In terms of 
dissemination, we will keep clubs updated on the prog-
ress of the study and will report the findings by email/
newsletter and in various meetings where club represen-
tatives are in attendance.
EthICs And dIssEMInAtIOn
All data will be collected and kept on National Health 
Service servers in accordance with the 1998 UK Data 
Protection Act, UoB and QEHB data handling and 
maintenance guidelines, with the minimum amount of 
required information recorded. The computers on this 
Table 1 SCRUM sample collection schema
Test
Time point
Baseline Pitch-side Postmatch
36–48 hours 
postinjury Stage V GRTP
Concussed player
  HIA X X (HIA1) X (HIA2) X (HIA3)
  Saliva X X X X X
  Urine X X X X
Orthopaedic control player
  HIA X
  Saliva X X X
  Urine X X X
Uninjured player
  HIA X
  Saliva X X X
  Urine X X X
GRTP, Graduated Return-to-Play protocol; HIA, Head Injury Assessment protocol; SCRUM, Study of Concussion in Rugby Union through 
MicroRNAs.
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network have restricted physical access; data are stored 
under coded file names and the local network has secure 
password access restricted to a limited set of people.
All the compiled and analysed results will be presented 
at national and international conferences concerning the 
care of the patients with traumatic brain injury. Results 
will also be submitted for peer review and publication in 
the subject journals/literature.
The datasets generated during and/or analysed during 
the current study are/will be available on request from 
AB who is the point of contact and will be able to provide 
anonymised data with sufficient details to reproduce the 
analyses for up to 10 years.
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